Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000950170-23-024629
Filing Date
2023-05-30
Accepted
2023-05-30 07:31:21
Documents
79
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 6-K frln-20230331.htm   iXBRL 6-K 1971459
2 EX-99.1 frln-ex99_1.htm EX-99.1 42714
3 GRAPHIC img173576535_0.jpg GRAPHIC 11135
4 GRAPHIC img173576535_1.jpg GRAPHIC 52459
5 GRAPHIC img173576535_2.jpg GRAPHIC 72154
  Complete submission text file 0000950170-23-024629.txt   8034997

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT frln-20230331.xsd EX-101.SCH 59388
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT frln-20230331_cal.xml EX-101.CAL 55573
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT frln-20230331_def.xml EX-101.DEF 219246
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT frln-20230331_pre.xml EX-101.PRE 348941
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT frln-20230331_lab.xml EX-101.LAB 424305
73 EXTRACTED XBRL INSTANCE DOCUMENT frln-20230331_htm.xml XML 1442232
Mailing Address SYCAMORE HOUSE GUNNELS WOOD ROAD, STEVENAGE HERTFORDSHIRE X0 SG1 2BP
Business Address SYCAMORE HOUSE GUNNELS WOOD ROAD, STEVENAGE HERTFORDSHIRE X0 SG1 2BP 44 (0)1438 906870
Freeline Therapeutics Holdings plc (Filer) CIK: 0001810031 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39431 | Film No.: 23971398
SIC: 2836 Biological Products, (No Diagnostic Substances)